EGFR and glioblastoma: In light of this, the updated 2021 WHO recommendations combined molecular and histologic features to diagnose glioblastoma based on isocitrate dehydrogenase (IDH) status, with glioblastoma diagnosed as IDH wildtype and showing either necrosis, microvascular proliferation, TERT promoter mutation, or EGFR gene amplification [32].